$XBI $123.26 +0.34%
Covid Updates
$MRNA -0.2% Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S. source
$SRNE -3.6% Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device source
$MOLN -0.3% Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference. source
Pipeline Updates
$ONCS 0.0% OncoSec Provides Business Update source
$MOR -0.8% MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy source
$EDIT -2.1% Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress. source
$CMPS +2.8% Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups. source
$RDUS +16.4% Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer.source
$FIXX -0.7% Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting. source
$LGVN -0.8% Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS).source
$NVAX -14.8% Novavax Reconfirms Confidence in Regulatory Filing Timelines and Manufacturing Quality. source
$KMPH +3.4% KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October).source
$VECT -0.6% VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease. source
$TCRR -8.6% TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day.source
$RCKT +3.0% Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT). source
$OBSV -1.8% ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo. source
Financial & Business Updates
$ADMA 0.0% ADMA Biologics Announces Proposed Public Offering of Common Stock source
$SWTX +0.8% SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics.source
$SWTX +0.8% SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors. source
Posted by FS/JM
Comments